Exploring Next Generation Drug Conjugates

Time: 3:30 pm
day: Day Two


  • Discover how PLEs represent a new class of drug conjugates using multiple therapeutic classes of payloads
  • Highlighting how the unique MoA facilitates killing of primary tumor cells, metastatic cells and CSCs and offers new treatment options for difficult to treat and refractory cancers
  • Examining how broad and versatile the potential of the PLE platform can be for treatment of different cancers